Background. The study sought to characterize the seroprevalence, seropersistence, and seroincidence of human papillomavirus (HPV)-16 antibody, as well as the behavioral risk factors for HPV-16 seropositivity.
Genital human papillomavirus (HPV) is a viral sexually transmitted disease (STD) of concern because of its high prevalence and causal role in cervical cancer [1] [2] [3] . More than 100 types of HPV have been identified, and types are generally classified as low or high risk, depending on their oncogenic potential [4] [5] [6] . HPV-16 mucosal DNA does not persist in most persons after infection [11, 12] , and attempts to detect it are prone to sampling error, so there has been interest in approaches-such as serum antibody measurement-that may provide a potentially better assessment of lifetime infection. Results of serologic assays appear to correlate better with cumulative past exposure than do DNA-based approaches [13] ; however, although highly type specific, they have variable sensitivity, possibly because of the poor immunogenicity of HPV infections in the superficial epidermis [14] [15] [16] . Seroepidemiologic studies to date have been primarily cross-sectional prevalence studies, have largely focused on women, and have generally found that the seroprevalence of HPV antibody is more strongly associated with lifetime sexual behavior than with more-recent sexual behavior [17] [18] [19] . There are relatively limited data that are relevant to the seroepidemiology of HPV infection in men [18, [20] [21] [22] and few longitudinal studies of HPV antibody that have assessed the persistence and incidence of HPV antibody in men or women [23] [24] [25] [26] [27] [28] . To better characterize the prevalence, persistence, and incidence of HPV-16 antibody in a high-risk group of women and men, we assessed serum samples collected, over 12 months, as part of Project RESPECT [29] .
SUBJECTS AND METHODS
Study population. Project RESPECT was a randomized controlled trial of risk-reduction counseling conducted between July 1993 and September 1996 at 5 public STD clinics (Baltimore, MD; Denver, CO; Long Beach, CA; Newark, NJ; and San Francisco, CA). The participants included heterosexual, HIVnegative patients у14 years old who were seeking care for STD [29] . Participants were randomized to 4 study arms, assessing 3 different counseling interventions. Subjects in 3 of the study arms had interviews at baseline and at 3, 6, 9, and 12 months, and examinations for STD and collection of serum samples occurred at baseline and at 6 and 12 months [29] . For this study, we considered only persons in the 3 arms with scheduled follow-up visits from 4 sites that had completely delinked individual patient identifying information from study data (Denver, San Francisco, Long Beach, and Baltimore), a total of 3445 participants. Of this group, 1595 patients for whom all 3 serum samples (i.e., at baseline and at 6 and 12 months) had been collected and were still retrievable were included. The original Project RESPECT protocol was approved by the institutional review board (IRB) at each site. Informed consent was obtained from all patients participating in the study. Human-experimentation guidelines of the US Department of Health and Human Services, as well as those of the participating institutions, were followed in the conduct of this research.
Study design. We performed a cross-sectional study to determine demographic and clinical predictors of prevalent HPV-16 seropositivity at baseline. We also performed a retrospective cohort study to assess predictors of both the seropersistence of HPV-16 antibody, in those who were HPV-16 seropositive at baseline, and incident HPV-16 seropositivity, in those who were HPV-16 seronegative at baseline. Prevalent HPV-16 seropositivity was defined as presence of serum HPV-16 antibody at baseline; persistent HPV-16 seropositivity was defined as the presence of HPV-16 antibody at baseline and at both followup visits; and incident HPV-16 seropositivity was defined as the development of HPV-16 antibody at the 6-or 12-month follow-up visit after a seronegative baseline sample. Individuals with a negative baseline test result who tested seropositive at 6 months and seronegative at 12 months were considered to have incident HPV-16 infections.
Baseline and follow-up interviews conducted in Project RESPECT provided information regarding patient demographics, sexual behavior, and other risk factors, for comparison with HPV-16 infection. Behavioral and clinical variables included age at first sexual intercourse, the number of lifetime sex partners, lifetime history of STD, whether sex had ever been provided in exchange for money or drugs, the number of episodes of sex with occasional partners during the preceding 3 months, percentage of condom use with all sex partners, the number of episodes of unprotected sex (i.e., without a condom) with occasional sex partners during the preceding 3 months, and the use of hormonal contraception by women. The circumcision status of men was determined by clinician examination at the baseline interview. The presence of other STDs (Neisseria gonorrhoeae, Chlamydia trachomatis, Treponema pallidum, Trichomonas vaginalis, and herpes simplex virus type 2 [HSV-2]) antibody at baseline and during follow-up was determined as described elsewhere [29] [30] [31] .
Serologic testing for HPV. Serum samples were stored at Ϫ70ЊC at the Centers for Disease Control and Prevention (CDC) in Atlanta, and were shipped to the laboratory of Dr. Michael Hagensee at Louisiana State University in New Orleans, where they were tested for the presence of HPV-16 antibody. The laboratory obtained IRB approval prior to serum testing. The serum samples were tested for HPV-16 IgG antibodies in a blinded fashion, by a capture ELISA assay [32] . Ninety-sixwell microtiter plates were coated with a monoclonal antibody specific for a conformational epitope on the L1 protein of HPV-16 (H16.V5, generously provided by Dr. Neil Christensen, Hershey Medical Center, Pennsylvania State University, Hershey) at 1:10,000 dilution in sodium carbonate buffer. The plates were blocked with Tris-buffered saline plus Tween and 10% goat serum (TBST-GS) and were coated with a dilution of 1: 50 in PBS of vaccinia virus-produced HPV viruslike particles (VLPs) of the same type. The coated plates were first incubated for 1 h, at 37ЊC, with human serum, at a dilution of 1:100 (in TBST-GS) and then were incubated for 1 h, at 37ЊC, with goat anti-human IgG antibody conjugated to alkaline phosphatase (1:1000 dilution in TBST-GS). Plates were developed by use of a Sigma 104 developer for exactly 30 min, and then the reaction was stopped by the addition of 1.5 mol NaOH/L. The resultant absorbency was read at 405 nm, by use of an ELx800 ELISA plate reader (Bio-tek Instruments). Each sample was tested in triplicate. Logarithmic transformation of raw data was performed, and, for each sample, the median of 3 wells without capsids was subtracted from the median of 3 wells with capsids (adjusted optical density [OD] ). The cut point for ELISA was determined simultaneously by screening childrens' (subjects !10 years old) serum samples for IgG antibodies against HPV-16. The 95th percentile for the adjusted OD values of control serum samples in each assay was used as the cut point. When this approach to the determination of the cut point was compared with approaches used in other studies (e.g., 2 SDs above the mean adjusted OD), the results did not vary [21, 22, 26] . Samples were tested in 3 separate batches, on the basis of when HPV-16 VLPs were available; all samples from an individual were tested in the same batch; the cut point was an adjusted OD of 0.261 for the first batch, 0.215 for the second batch, and 0.228 for the third batch. Statistical analysis. Point prevalence, 95% confidence interval (CI), and odds ratio (OR) were calculated by standard methods [33] and SAS software version 8.1 (SAS Institute). McNemar's test was used to evaluate the relationship between the seroprevalence of HPV-16 antibody at baseline and that at year 1 of follow-up. Univariate and simple multiple logisticregression analyses were performed to examine the association between the seroprevalence and seropersistence of HPV-16 antibody and demographic, STD-history, and sexual-behavior variables. A multiple logistic-regression model was created with (1) baseline-interview variables that were significant ( or P ! .05 moderate/large OR) on the basis of univariate logistic regression and (2) baseline-interview variables considered to be potential confounders and interaction terms. A manual backward-elimination process was used to eliminate, on the basis of the likelihood-ratio test, variables that either were not independent predictors or, when the x 2 distribution for significance was used, did not significantly change the multiple logistic-regression model. All models were adjusted for study site and test batch; models were created for all study subjects, and then separate models were created for men and for women, to explore sexspecific variables (i.e., the circumcision status of men and the use of hormonal contraception by women) and to better assess sex differences in risk factors for seropositivity. The seroprevalence control group were those individuals who were HPV-16 seronegative at baseline, whereas the seropersistence control group were those who were HPV-16 seropositive at baseline who had a subsequent HPV-16-seronegative result. The seroincidence (and 95% CI) of HPV-16 antibody, per 100 person-years (py) of follow-up, was calculated by standard methods [33] . Independent predictors of incident HPV 16 seropositivity were assessed by a discrete-survival, multiple logistic-regression model. Because serum samples were drawn at baseline and at the 6-and 12-month follow-up visits, there were 2 6-month intervals that began and ended with an HPV-16 assay. Quarterly interviews asked about behavior during the preceding 3 months, so behavioral-questionnaire data for each 6-month interval combined the 2 interviews conducted during that interval; therefore, only persons available at all 3 visits during either the first interval (i.e., baseline visit and visits at 3 and 6 months) or the second interval (i.e., visits at 6, 9, and 12 months) could be included. Data were analyzed in terms of these 6-month intervals. A multiple logistic-regression model was created by use of (1) behavioral data collected at the 6-month intervals and (2) demographic and potential confounding variables; then modeling was conducted in the same manner as was used for the analysis of the seroprevalence of HPV antibody.
RESULTS

Demographic data.
The descriptive characteristics of the study population are presented in table 1. Patients excluded from the study ( ) were slightly younger, had lower income and n p 1850 education, and were more likely to be black and from Baltimore than were the 1595 patients included in the study. Among those included, there were similar percentages of women and men. Blacks constituted the largest racial/ethnic group in the study, followed by whites and Hispanics. The age groups with the greatest representation were the 20-25-year-olds and the 26-35-year-olds. The mean age and the median number of lifetime sex partners were greater in men, and the mean age at first sexual intercourse was lower in men.
Seroprevalence 27 .5% overall and is 31.8% for women and 22.9% for men. The seroprevalence of HPV-16 antibody also varied by city, ranging from 20.5% in San Francisco to 29.9% in Denver. Finally, the seroprevalence of HPV-16 antibody was also significantly associated with whether sex had ever been provided in exchange for money or drugs, a history of syphilis, the presence of HSV-2 antibody, the number of occasional sex partners during the preceding 3 months, the number of episodes of sex with occasional partners during the preceding 3 months, and the number of episodes of unprotected sex with occasional partners during the preceding 3 months.
Variables that multiple logistic regression found to be independent predictors of the seroprevalence of HPV-16 antibody are shown in table 2. Female sex was the factor most strongly associated with HPV-16 seropositivity, with women being twice as likely as men to be seropositive. Age too was associated with a higher seroprevalence of HPV-16 antibody, with HPV-16 seropositivity being more common in all age groups 120 years than in adolescents. Other variables independently associated with the seroprevalence of HPV-16 antibody were the number of episodes of sex with occasional sex partners and study site; variables not so associated were HSV-2 seropositivity, whether sex had ever been provided in exchange for money or drugs, the number of occasional sex partners, and the number of episodes of unprotected sex with occasional partners.
Separate multiple logistic-regression models were created to assess risk factors in women and in men. In women, race/ Downloaded from https://academic.oup.com/jid/article-abstract/190/9/1563/880387 by guest on 10 April 2019 ethnicity, age, and the number of episodes of sex with occasional sex partners were the strongest predictors of the seroprevalence of HPV-16 antibody. White women were more likely to be HPV-16 seropositive (OR, 1.6 [95% CI, 1.1-2.4]) than were other women, and women 120 years old were more likely to be seropositive (OR, 1.8 [95% CI, 1.1-2.9]) than were women !20 years old. Women with 3-10 episodes of sex with occasional sex partners were more likely to be seropositive (OR, 1.9 [95% CI, 1.3-2.9]) than were women with no occasional sex partners. The number of lifetime sex partners, the number of sex partners during the preceding 3 months, or the number of occasional sex partners; history of STD; condom use with all or occasional sex partners; and the use of hormonal contraception by women were not associated with HPV-16 seropositivity. In men, HPV-16 seropositivity was associated with race/ethnicity, age, and the number of occasional sex partners. In contrast to its race/ethnicity distribution in women, the seroprevalence of HPV-16 antibody was highest in Hispanic men, who were twice as likely (OR, 2.0 [95% CI, 1.0-3.8]) as white men to be seropositive. Men 120 years old were also more likely (OR, 3.4 [95% CI, 1.4-7.8]) to be seropositive, and men who reported having had 1 occasional sex partner were more likely (OR, 1.7 [95% CI, 1.1-2.8]) to be seropositive than were men with no occasional sex partners. There was no association with the circumcision status of men. As for women, there was no association with the number of lifetime sex partners or the number of sex partners during the preceding 3 months, condom use, or history of STD.
Seropersistence of HPV-16 antibody. In the 391 participants who were HPV-16 seropositive at baseline, there were 4 types of serologic responses during the 1-year follow-up-after the baseline seropositive result, 68 (17.4%) were seronegative at the 6-and 12-month follow-up visits, 35 (9.0%) were seronegative at the 6-month follow-up visit and then were seropositive at the 12-month follow-up visit, 44 (11.3%) were seropositive at the 6-month follow-up visit and then were seronegative at the 12-month follow-up visit, and 244 (62.4%) were seropositive at both the 6-and the 12-month follow-up visits and thus were considered to have a persistent antibody response. The mean adjusted OD for each of these 4 serologicresponse groups showed distinct patterns, with substantially higher mean adjusted baseline OD values in those who had persistent seropositivity than in those who did not (0.69 vs. 0.36, respectively; ) (figure 1). P ! .0001 By univariate analysis, the most important predictors of persistent seropositivity were female sex and adjusted baseline OD. Antibody persisted in 72.5% of women versus 45.6% of men ( ). Subjects with an adjusted baseline OD value higher P ! .05 than the 0.443 median adjusted OD value for subjects with prevalent HPV-16 seropositivity were twice as likely to have a persistent antibody response as those with lower baseline values (93.5% vs. 45.2%;
). In multivariate analysis, the sero- ). Mean P ! .05 adjusted baseline OD levels were higher among those who seroconverted than those who did not (0.06 vs. 0.03; ) (figure P ! .05 2) but did not vary between those who were transiently positive, those who were persistently positive, and those who did not seroconvert until 12 months.
In univariate analysis, characteristics associated with incident HPV-16 seropositivity included female sex, the number of episodes of unprotected sex with occasional partners, and baseline HSV-2 seropositivity (table 3) . In addition, an adjusted baseline OD value higher than the median value of 0.045 was associated with incident HPV-16 seropositivity. Neither intervention arm nor any variable that measured baseline or incident STD or sexual behavior during follow-up was associated with incident HPV-16 seropositivity. In multivariate analysis, female sex, the number of episodes of unprotected sex with occasional partners, and an adjusted baseline OD higher than the median continued to be associated with incident HPV-16 seropositivity, as did age 120 years.
Separate multiple logistic-regression models of incident HPV-16 seropositivity were created for men and for women. In women, significant predictors were high adjusted baseline OD (OR, 1.7 [95% CI, 1.1-2.6]) and having had 11 Finally, to further explore trends in HPV-16 seropositivity over time, the seroprevalences of HPV-16 antibody at baseline and at year 1 of follow-up were compared by sex and by age (table 4). As a result of the higher seroincidence and seropersistence of HPV-16 antibody in women, the seroprevalence of HPV-16 antibody in women was significantly higher at year 1 than at baseline (37.1% vs. 30.2%, respectively; ), a P ! .0001 result that was not observed in men (17.7% vs. 18.7%, respectively). In those !20 years or 20-24 years old, the seroprevalence of HPV-16 antibody was higher at year 1 of followup than at baseline, a result not observed in those 26-35 or 135 years old.
DISCUSSION
The present study of HPV-16 seropositivity is one of the few to include both men and women and, to our knowledge, is the first to evaluate the seropersistence and seroincidence, as well as the seroprevalence, of HPV-16 antibody. In the present study, the seroprevalence of HPV-16 antibody was 24.5% overall and was 30.2% in women and 18.7% in men. Of individuals with a seroprevalent HPV-16 infection, 62.4% had seropersistent HPV-16 antibody during the 12-month follow-up interval, with the seropersistence being greater in women than in men. Finally, in the 75% of individuals who were HPV-16 seronegative at baseline, the seroincidence of HPV-16 antibody was surprisingly high, 20.2/100 py, with a rate of 25.4/100 py in women and 15.7/100 py in men.
The present study's 20% estimated annual seroincidence of HPV-16 antibody is higher than those which Project RESPECT found for the most frequent STDs (i.e., chlamydia-7.3%, by PCR; gonorrhea-6.3%, by culture; and HSV-2-11.7%, by typespecific serologic testing) [29, 30] , a finding consistent with other projections of relative levels of incidence of STD [34] . However, the present study's measure of incident HPV-16 seropositivity is only an approximation and is limited by several methodological issues. On the one hand, the median time to seroconversion in women with known incident HPV-16 seropositivity is estimated to be 8.3-11.8 months [25, 26] , indicating that many of the cases of incident HPV-16 seropositivity that were detected at 6 months may have been acquired before individuals were enrolled in the study. This may have resulted in an overestimation of the seroincidence of HPV-16 antibody during the study period. This possibility is supported by the finding that the adjusted baseline OD value was one of the strongest predictors of incident HPV-16 seropositivity, suggesting that some individuals may have been seroconverting at baseline. On the other hand, HPV-16 serum antibody, although believed to be specific [24, 35, 36] , is an insensitive measure of infection, with only 50%-70% of women with incident HPV-16 seropositivity, as measured by the detection of mucosal HPV DNA, developing a systemic antibody response [8, 26, 36] , a phenomenon that causes an underestimation of the seroincidence of HPV-16 antibody.
The difference that the present observed between the seroprevalence of HPV-16 antibody in men and that in women is consistent with the results of previous studies, although the rates of infection have varied depending on the population [18, 20, 21] . The lower rates of seropersistence and seroincidence of HPV-16 antibody men, compared with those in women, have not previously been reported. The differences, by sex, in the seroprevalence, seropersistence, and seroincidence of HPV-16 antibody remained after adjustment for other factors, supporting the premise that there are biological reasons for men's and women's differing serologic responses [18] . Because the men in the present study reported similar or even higher sexual risk factors and exposures than did women, it is unlikely that they were less frequently exposed to HPV-16; rather, it is possible that men are either not as susceptible to HPV-16 infection or more frequently able to clear the infection spontaneously without developing a systemic antibody response. The fact that men's sexual exposure to HPV infections more commonly involves keratinized epithelium (i.e., penis)-rather than the mucosal epithelium (i.e., cervix), which is more commonly involved in women-may reduce either the likelihood of HPV-16 infection or the induction of a detectable systemic antibody response [20, 21] . The greater mucosal surface in uncircumcised men has been associated with the incidence of the detection of HPV DNA [37] , although the present study found that the circumcision status of men was not associated with the seroprevalence and seroincidence of HPV-16 antibody.
For both the prevalence and incidence of HPV-16 infection, the present study found no association with longer-term measures of sexual behavior (e.g., the number of lifetime sex partners) but did find associations with measures of sexual behavior during the preceding 3 months, primarily sexual contact with occasional partners. That incident HPV-16 seropositivity should be related to sexual behavior during the preceding 3 months is to be expected, but the present study's inability to find an association between prevalent HPV-16 seropositivityand longer-term behavior is surprising, given that virtually all previous studies of the seroprevalence of HPV-16 antibody, both in higher-risk environments such as STD clinics [17, 20] and in lower-risk settings such as family-planning clinics or population-based surveys [18, 19, 38, 39] , have found associations with the number of lifetime sex partners. It is important to note, however, that many of these previous studies did not evaluate recent sexual behavior [20, 35, 38, 39] ; an important exception is the only other study of a US STD-clinic population [21] , which found no relationship with lifetime sex partners, for the seroprevalence of either HPV-16 antibody or HPV-6 antibody, but which did find, for the latter, an association with the number of recent sex partners. Persons seeking care in an STD clinic do so because of perceived or actual recent exposure to an STD and thus are also at risk for exposure to another STD. Therefore, it is likely that, in such high-risk populations, a greater proportion of seroprevalent infection is due to recently acquired rather than long-standing infection, a hypothesis supported by the present study's observation that the level of seroincidence of HPV-16 antibody during follow-up (19.0%) was similar to that at baseline (24.5%).
There are few published data regarding rates and predictors of persistent HPV antibody. In a study of women with incident HPV-16 seropositivity, 71% of seroconverters remained seropositive over a follow-up period that lasted up to 4 years [26] , whereas a study of pregnant women in Finland who had prevalent HPV-16 antibody documented 198% persistence over a follow-up period that lasted up to 5 years [27] . The present study's finding that antibody persisted in 73% of women who were seropositive at baseline, a rate similar to that found in newly sexually active college women in the Carter studies [25, 26] , supports the hypothesis that many of these women may have been infected recently. In addition, the present study's observation that the adjusted baseline OD predicts the seropersistence of HPV-16 antibody is consistent with the Finnish study's findings [27] .
The present study has several potential limitations. Because of the imperfect sensitivity of serologic tests for HPV [14, 24, 25] , misclassification bias was an issue for the present study, as it is for other seroepidemiologic studies of HPV. The 95th-percentile cut point was chosen to maintain a high level of specificity, although it may have reduced the sensitivity-and, thereby, may have underestimated the rate of seropositivity. A different degree of such misclassification across studies may explain some of the differences seen across them. Furthermore, the present study's cohort was derived from a group that is at higher risk than is the general US population, and therefore its results are likely not generalizable to nonurban, non-STD-clinic populations. Finally, the present study was able to include only 46.3% of eligible Project RESPECT participants, which also limits generalizability.
Despite these limitations, the present study provides important information about HPV-16 seropositivity and associated risk factors. It confirms the large burden of prevalent and incident HPV-16 seropositivity seen in sexually active adults and emphasizes the importance of female sex as a predictor of the seropersistence and seroincidence of HPV-16, as well as the seroprevalence, of HPV-16 antibody. It also raises the question of the potential contribution of recent sexual behavior to the measured seroprevalence of HPV-16 antibody. The exciting potential of highly effective prophylactic HPV vaccines [40] highlights the importance of developing better approaches to surveillance and epidemiology of genital HPV infection, in order to monitor both the burden of infection in the population and the impact that prevention programs might have on its control.
